semaglutide for chronic kidney disease in patients with overweight or obesity and without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide: A Breakthrough for Chronic

We welcome your reactions: What do you think

The Department of Health reports 40 percent of adults in the state are considered obese, compared to about 33 percent nationwide

Br J Nutr 93(6):845851 Alvarez E, Martnez MD, Roncero I, Chowen JA, Garca-Cuartero B, Gispert JD et al (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem

However, the SUSTAIN six trial evaluated semaglutide, a GLP-1 analog, in patients with type 2 diabetes and high cardiovascular risk and discovered that semaglutide was associated with a higher incidence of diabetic retinopathy complications compared to placebo, with a hazard ratio (HR) of 1.76, particularly in patients with pre-existing DR (Vilsbll et al., 2018)